Please login to the form below

Not currently logged in
Email:
Password:

psoriatic arthritis

This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.

J&J's Tremfya filed for approval in US for psoriatic arthritis

J&J's Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market. Johnson &Johnson has submitted an application to the FDA for the approval of Tremfya in psoriatic arthritis, which could further congest an intensely competitive ... This includes Novartis’

Latest news

More from news
Approximately 14 fully matching, plus 114 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics